About Mark Waring
Dr. Waring is a licensed physician with clinical experience in internal medicine and a research background in endocrinology and neuropharmacology. He also holds a Master degree in epidemiology and statistics. Dr. Waring has over 20 years of industry and consulting experience in clinical drug safety and post-marketing pharmacovigilance, pharmacoepidemiology and pharmaceutical safety risk management.
Dr. Waring has led or supported the design and preparation of dozens of risk management plans for a wide range of products, ranging from pragmatic, cost-effective approaches to complex plans deployed for major products in an environment of significant public interest and regulatory scrutiny. He has authored numerous periodic safety reports in various formats for a wide array of investigational and marketed medicinal products, comprehensively evaluated numerous safety signals and provided the necessary safety expertise during a number of pharmacovigilance audits and due diligence activities. Across all of these projects, he has an immaculate track record of a diligent and ethical approach and on-time delivery of high-quality results meeting regulatory expectations - at a competitive price.
Dr. Waring's medical expertise and operational routine is complemented by a thorough understanding of global and EU pharmacovigilance system requirements. He has led or supported pharmacovigilance system quality improvement initiatives in several companies and trained and coached many individuals in the field of pharmacovigilance and pharmacoepidemiology. His particular areas of interest include the evaluation of drug hepatotoxicity and the safety of biological therapeutics.